<DOC>
	<DOCNO>NCT02445742</DOCNO>
	<brief_summary>Prospective , open label , multicenter , phase II study evaluate correlation SNPs efficacy toxicity patient treat Bosutinib . A total 50 patient previously treat Ph+ chronic phase CML include study</brief_summary>
	<brief_title>CML Treated With Bosutinib After Relapse</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<criteria>Signed date informed consent form . Patients chronic Ph + CML present nonoptimal response 3 month prior ITK treatment ( imatinib , nilotinib , dasatinib ) . It define nonoptimal response : BCRABL &gt; 10 % per qRTPCR ( IS ) 3 month initiation treatment . BCR / ABL ≥ 1 % per qRTPCR ( IS ) 6 month initiation treatment . BCR / ABL &gt; 0.1 % qRTPCR ( IS ) 12 month initiation treatment . BCRABL1 &gt; 0.1 % qRTPCR ( IS ) time 12 month treatment initiation . ECOG Performance Status 0 1 . Recovery Grade 01 , baseline value pretreatment toxicity , except alopecia . Cases significant toxicity analyze individually study coordinator Able take daily oral capsule Adequate bone marrow function : 1 . Absolute neutrophil count &gt; 1000/mm3 ( &gt; 1000 x109/L ) 2 . Platelets ≥ 100,000/mm3 ( &gt; 100 x109/L ) 3. absent platelet transfusion precede 14 day . Adequate hepatic , renal function : AST/ALT ≤ 2.5 × upper limit normal ( ULN ) ≤ 5 × ULN attributable liver involvement leukemia Total bilirubin ≤ 1.5 × ULN Creatinine ≤ 1.5 × ULN Age &gt; 18 year Willingness male female subject , surgically sterile postmenopausal , use reliable method birth control ( oral contraceptive , intrauterine device , barrier method use spermicide ) duration study 30 day last dose Bosutinib . Exclusion Criteria Subjects Philadelphia chromosome bcrabl negative CML . Overt leptomeningeal leukemia . Subjects must free CNS involvement minimum 2 month . Subjects symptoms CNS involvement must diagnostic lumbar puncture prior study enrollment . Subjects extramedullary disease . Prior stem cell transplantation . Major surgery within 14 day radiotherapy within 7 day first dose Bosutinib ( recovery previous surgery complete day 1 ) A history clinically significant ventricular arrhythmia , congenital acquire prolonged QT interval , baseline QTcF &gt; 0.47 sec ( average triplicate reading ) unexplained syncope , uncontrolled symptomatic congestive heart failure ( CHF ) within 3 month , myocardial infarction ( MI ) within 6 month . Concomitant use need medication know prolong QT interval Uncorrected hypomagnesemia hypokalemia due potential effect QT interval Recent ( within 30 day study entry ) ongoing clinically significant gastrointestinal disorder ( e.g. , malabsorption , short bowel syndrome , bleeding , grade &gt; 1 diarrhea , nausea emesis last 2 day , despite adequate medical therapy ) Pregnant breastfeed woman Evidence serious active infection , significant medical psychiatric illness Known seropositivity HIV , current acute chronic Hepatitis B Hepatitis C ( antigen positive ) , cirrhosis , hypokalemia ( grade ) , clinically significant abnormal laboratory find would , investigator 's judgment , make subject inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic Myeloblastic Leukaemia</keyword>
</DOC>